Topics covered:
1. Trilaciclib's approval to minimize bone marrow suppression
2. Cemiplimab's approval for mNSLC with high PD-L1 expression
3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma
4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer
5. More of the same with lenvatinib + pembrolizumab in mRCC
